Pharma BD Deal Intelligence
Business Standard reported the deal as the largest-ever US acquisition by an Indian pharma company, framing it as a strategic counter to US generic price…
Law360 reported the $880M cash deal as a landmark transaction in the consolidating US generics space, with Brown Rudnick advising Lupin on the largest US…
GaBI Online characterized the Gavis acquisition as Lupin's springboard to the fifth-largest US ANDA portfolio and its first US manufacturing footprint,…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Lupin agreed to acquire US generics maker Gavis Pharmaceuticals and Novel Laboratories for $880M, the largest US acquisition by an Indian pharma at the time. Provided Lupin its first US manufacturing facility (New Jersey) and broadened pipeline in dermatology and controlled substances.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lupin Limited / Gavis Pharmaceuticals LLC and Novel Laboratories, Inc. (this deal) | 2015 | $880M | 48 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| LEO Pharma A/S / AstraZeneca PLC | 2016 | $1.1B | 80 |
← Browse all deals · How we score deals
More: 2015 deals · Dermatology deals